Pfizer’s corona oral drug, online sales in China sold out immediately | Reuters

On December 13, Chinese online drug sales company Inc. began selling Pfizer’s novel coronavirus oral treatment Paxlobide. A photo of the Pfizer logo. FILE PHOTO: Pourse, Belgium, June 2, 2022. REUTERS/Johanna Geron

BEIJING (Reuters) – Chinese online drug retailer Inc. began selling Pfizer Inc.’s oral COVID-19 treatment Paxlobide on Wednesday. This is believed to be the first time that Paxlobide has been sold to general consumers in China.

The price is 2,980 yuan ($426.80) per box, according to’s website. You can purchase it on the app if you submit a positive result of the new corona test.

According to customer service, it sold out an hour and a half after it was announced.

It is unclear how many boxes have been sold, when sales will resume, or whether other retailers will carry the product.

Paxlobide was approved in China in February and is available through hospitals in several provinces for the treatment of high-risk patients.